Kestra Advisory Services LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 70.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,339 shares of the medical research company’s stock after purchasing an additional 3,869 shares during the quarter. Kestra Advisory Services LLC’s holdings in IQVIA were worth $2,511,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of IQVIA during the 2nd quarter worth about $2,811,292,000. Canada Pension Plan Investment Board acquired a new position in IQVIA in the 2nd quarter valued at about $240,911,000. Bank of America Corp DE bought a new position in IQVIA in the 2nd quarter valued at about $235,551,000. Legal & General Group Plc bought a new position in IQVIA in the 2nd quarter valued at about $211,342,000. Finally, Bank of New York Mellon Corp acquired a new stake in IQVIA during the second quarter worth approximately $180,296,000. Institutional investors and hedge funds own 89.62% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on IQV. Weiss Ratings cut IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a report on Wednesday, October 28th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. HSBC increased their target price on IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, September 1st. UBS Group initiated coverage on IQVIA in a report on Wednesday, September 30th. They set a “buy” rating and a $345.00 price target for the company. Finally, Rothschild & Co Redburn boosted their price target on IQVIA from $284.00 to $287.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.
Check Out Our Latest Stock Analysis on IQVIA
IQVIA Price Performance
NYSE:IQV opened at $265.44 on Monday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $284.50. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The firm’s 50-day simple moving average is $267.55 and its 200 day simple moving average is $211.88. The firm has a market cap of $43.74 billion, a price-to-earnings ratio of 32.25, a P/E/G ratio of 2.36 and a beta of 1.16.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the previous year, the firm posted $3.00 EPS. The business’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.
Insider Activity at IQVIA
In other news, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.70% of the stock is currently owned by company insiders.
IQVIA Profile
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Further Reading
- Five stocks we like better than IQVIA
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
